Richard Shelby actually said...

Today's hearing will examine the difficult task of defining and regulating systemic risk.

It seems like that's an ideal opportunity for academia to team with industry to bring treatments to patients faster.

I support Federal investment in basic biomedical research and development.

As research becomes more expensive and private capital dries up, I believe it's critical to ensure support for translational research.